Media - Comunicati Stampa

Per le attività relative a Press & Communication prego contattare:
CITYnet communication
Rome, ITALY
press@sifigroup.com

Visita i nostri social channel!

Comunicati Stampa

Per le attività relative a Press & Communication prego contattare: CITYnet communication Rome, ITALY press@sifigroup.com Visita i nostri social channel!

Comunicati Stampa

SIFI ANNOUNCES LICENSE AGREEMENT WITH AVANZANITE BIOSCIENCE FOR AKANTIOR®10 Gennaio 2023

SIFI ANNOUNCES LAUNCH OF EPICOLIN, COMPREHENSIVE SUPPLEMENT IN THE TREATMENT OF GLAUCOMA05 Dicembre 2022

SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR® in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago13 Ottobre 2022

SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS15 Settembre 2022

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM07 Giugno 2022

Comunicati Stampa

SIFI ANNOUNCES LICENSE AGREEMENT WITH AVANZANITE BIOSCIENCE FOR AKANTIOR®
10 Gennaio 2023

SIFI ANNOUNCES LAUNCH OF EPICOLIN, COMPREHENSIVE SUPPLEMENT IN THE TREATMENT OF GLAUCOMA
05 Dicembre 2022

SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR® in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago
13 Ottobre 2022

SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS
15 Settembre 2022

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM
07 Giugno 2022